Nature 612 , 720724 (2022)
Matthias Tschp and Richard DiMarchi developed the first dual and triple agonist weight loss drugs
161 In summary, dual and triple agonists related to GLP-1 represent significant advances in the field of diabetes treatment, 167,168 demonstrating the future trend of enhancing therapeutic effects by targeting multiple biomarkers
Individuals with a BMI of 30 kg/m or higher may qualify directly, while those with a BMI of 27 kg/m or higher may be eligible if they have weight-related health conditions like hypertension, type 2 diabetes , elevated cholesterol, or obstructive sleep apnea
Notes on GI symptoms by dose phase
In a CY-5 experiment, replacing position 13 with Aib rendered the agonist inactive toward GCGR and slightly altered GLP-1 and GIP activity